title: [Effectiveness of typical and atypical neuroleptics in the control of behavioral and psychopathological symptoms of dementia. Results of a retrospective study].
abstract: BACKGROUND
  Presence of disruptive behavioural and psychological symptoms in dementia (BPSD) is highly prevalent and, as a consequence, neuroleptics are frequently used in these patients to control BPSD. Several reviews have shown the clinical equivalence of different classes of neuroleptics in BPSD control, although that equivalence has been only indirectly assessed by comparing the combined results of different types of active drugs versus placebo. Thus, little is known on the comparative effectiveness, head to head, of different neuroleptics on BPSD. The aim of this study was to gather preliminary information on the effectiveness of typical (haloperidol, thioridazine) and atypical (olanzapine, risperidone) neuroleptics on BPSD.
  
  
  METHODS
  Multicenter, observational and retrospective study using chart reviews of patients with dementia to assess neuroleptic prescriptions and clinical outcomes at 12 weeks on treatment.
  
  
  RESULTS
  No significant differences on BPSD improvement were found by type of neuroleptic (n=78; Kruskal- Wallis exact test; p=0.47). There also were no differences by neuroleptics when the analysis was stratified by levels of cognitive decline (Kruskal-Wallis exact test; p=0.86 and 0.87 for moderate and severe levels of deterioration, respectively). Recorded side effects were worse in the haloperidol group (n=19) regarding rigidity (Fisher's exact; p=0.01), tremor (Fisher's exact p=0.03) and akathisia (Fisher's exact; p=0.03).
  
  
  CONCLUSIONS
  Our findings support the equivalence in effectiveness of several classes of neuroleptics commonly used to treat BPSD. Nevertheless these results need to be confirmed by adequately powered randomized trials and further pharmacoepidemiological studies to assess their safety.
authors.affiliation: Clínica Psiquiátrica Padre Menni, Pamplona, Instituto de Investigaciones Psiquiátricas, Bilbao. dmedica@mennipam.com
authors.forename: M
authors.initials: M
authors.lastname: Martin Carrasco
authors.forename: J
authors.initials: J
authors.lastname: Ballesteros
authors.forename: A
authors.initials: A
authors.lastname: Bulbena
authors.forename: G
authors.initials: G
authors.lastname: Baraibar
authors.forename: C
authors.initials: C
authors.lastname: García
authors.forename: L
authors.initials: L
authors.lastname: Minguez
authors.forename: J
authors.initials: J
authors.lastname: Blanco
authors.forename: J
authors.initials: J
authors.lastname: de Blas
authors.forename: J A
authors.initials: JA
authors.lastname: Agüero
authors.forename: N
authors.initials: N
authors.lastname: Ibarra
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003704:Dementia / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000209:etiology*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents